Study Fails to Confirm L-Carnitine Benefits in Dialysis Patients

Share this article:

A new meta-analysis has found that L-carnitine does not significantly increase hemoglobin or decrease the required erythropoietin dose in patients on maintenance hemodialysis (MHD), contrary to a previous meta-analysis. L-cartinine, however, significantly decreases serum levels of low-density lipoprotein (LDL) and C-reactive protein (CRP).

Yizhi Chen, MD, of the Chinese People's Liberation Army Medical Academy in Beijing, and collaborators analyzed data from 49 randomized controlled trials examining the effects of L-carnitine in adult MHD patients. L-carnitine decreased the mean LDL level by 5.82 mg/dL and mean CRP level by 3.65 mg/L, the investigators reported online ahead of print in the American Journal of Clinical Nutrition. L-carnitine had no significant effect on triglycerides, total cholesterol, high-density lipoprotein, hemoglobin, hematocrit, albumin, or the required erythropoietin dose.

Share this article:
You must be a registered member of RUN to post a comment.

More in Hemodialysis

Wearable Artificial Kidney Greenlit For Safety Testing

Wearable Artificial Kidney Greenlit For Safety Testing

Researchers expect to start safety and performance testing of the Wearable Artificial Kidney (WAK) this autumn.

Lower Cardiovascular (CV) Death Risk in Dialysis Patients with High Sclerostin

Lower Cardiovascular (CV) Death Risk in Dialysis Patients ...

The highest tertile of sclerostin level is associated with a 71% decreased risk of cardiovascular death vs. the lowest tertile.

Study Shows Benefit of Twice-Weekly Hemodialysis

Study Shows Benefit of Twice-Weekly Hemodialysis

Better preservation of residual kidney function with twice-weekly than thrice-weekly hemodialysis in the first year.